T1	Participants 238 298	patients who will benefit from targeted anticancer therapies
T2	Participants 385 598	455 women with invasive human epidermal growth factor receptor 2 (HER2)-positive breast cancer and compared rates of pathologic complete response (pCR) to neoadjuvant lapatinib, trastuzumab, and their combination.
